Toggle light / dark theme

An already-approved chemotherapy drug could reduce the risk of dying of cervical cancer when added to the current treatment standard, according to new research presented at a major medical conference.

The study, presented at the European Society for Medical Oncology, followed 500 people, most of whom had “locally advanced” cervical cancer that hadn’t yet spread to other body parts.

Half of the patients were treated with chemoradiation — the current gold standard for treatment, researchers said. The other half were given combination therapy that included a pre-dose (or induction dose) of chemotherapy before every session of chemoradiation.

How many qubits do we have to have in a quantum computer and accessble to a wide market to trully have something scfi worthy?


Today, a startup called Atom Computing announced that it has been doing internal testing of a 1,180 qubit quantum computer and will be making it available to customers next year. The system represents a major step forward for the company, which had only built one prior system based on neutral atom qubits—a system that operated using only 100 qubits.

The error rate for individual qubit operations is high enough that it won’t be possible to run an algorithm that relies on the full qubit count without it failing due to an error. But it does back up the company’s claims that its technology can scale rapidly and provides a testbed for work on quantum error correction. And, for smaller algorithms, the company says it’ll simply run multiple instances in parallel to boost the chance of returning the right answer.

Computing with atoms

Atom Computing, as its name implies, has chosen neutral atoms as its qubit of choice (there are other companies that are working with ions). These systems rely on a set of lasers that create a series of locations that are energetically favorable for atoms. Left on their own, atoms will tend to fall into these locations and stay there until a stray gas atom bumps into them and knocks them out.

FGFR inhibitors, in combination with standard treatments, have extended the lives of many with this disease. However, these drugs often stop working after six to eight months.

“These drugs work very well for a while, but resistance is inevitable,” says gastrointestinal medical oncologist Milind Javle, M.D.

Now, a new type of FGFR inhibitor may allow patients to live longer without their disease progressing.

Data that needs to be stored long-term is growing exponentially. Existing storage technologies have a limited lifetime, and regular data migration is needed, resulting in high cost. Project Silica designs a long-term storage system specifically for the cloud, using quartz glass.

Read the blog at https://aka.ms/AA6faho.
Learn more about the project at https://www.microsoft.com/en-us/research/video/project-silic…-in-glass/